Cogent Biosciences (COGT) Depreciation & Amortization (CF) (2017 - 2026)
Cogent Biosciences (COGT) recorded quarterly Depreciation & Amortization (CF) of $626000.0 in Q1 2026, down 5.72% quarter-over-quarter from $664000.0 in Q4 2025, and down 2.19% on a YoY basis from $640000.0 in Q1 2025.
Cogent Biosciences (COGT) Depreciation & Amortization (CF) (2017 - 2026) Analysis & Trends
Cogent Biosciences' Depreciation & Amortization (CF) history runs 10 years deep, the most recent figure standing at $626000.0 for Q1 2026.
- In Q1 2026, Depreciation & Amortization (CF) fell 2.19% year-over-year to $626000.0; the TTM figure through Mar 2026 stood at $2.6 million (up 1.77% YoY), while the FY2025 annual figure was $2.6 million, up 4.0% from the prior year.
- Depreciation & Amortization (CF) was $626000.0 for Q1 2026 at Cogent Biosciences, down from $664000.0 in the prior quarter.
- In the past five years, Depreciation & Amortization (CF) ranged from a high of $675000.0 in Q4 2024 to a low of $69000.0 in Q1 2022.
- Historically, Depreciation & Amortization (CF) has averaged $519176.5 across 5 years, with a median of $606000.0 in 2024.
- The sharpest annual moves came in 2023 and 2026: Depreciation & Amortization (CF) surged 666.67% in 2023, then slipped 2.19% in 2026.
- A 5-year view of Depreciation & Amortization (CF) shows it stood at $378000.0 in 2022, then soared by 66.14% to $628000.0 in 2023, then gained by 7.48% to $675000.0 in 2024, then declined by 1.63% to $664000.0 in 2025, then retreated by 5.72% to $626000.0 in 2026.
- The last three Depreciation & Amortization (CF) figures came in at $626000.0 (Q1 2026), $664000.0 (Q4 2025), and $641000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | 1,395.22 |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | - |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | - |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | -1,330.00 |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | 55.90 Mn |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | 429,663.65 |
| 10 | Cogent Biosciences | 5.09 Bn | 4.22 Bn | - | 626,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 626,000.00 |
| Mar 31, 2026 | 626,000.00 |
| Dec 31, 2025 | 664,000.00 |
| Dec 31, 2025 | 664,000.00 |
| Sep 30, 2025 | 641,000.00 |
| Sep 30, 2025 | 641,000.00 |
| Jun 30, 2025 | 655,000.00 |
| Jun 30, 2025 | 655,000.00 |
| Mar 31, 2025 | 640,000.00 |
| Mar 31, 2025 | 640,000.00 |
| Dec 31, 2024 | 675,000.00 |
| Dec 31, 2024 | 675,000.00 |
| Sep 30, 2024 | 620,000.00 |
| Sep 30, 2024 | 620,000.00 |
| Jun 30, 2024 | 606,000.00 |
| Jun 30, 2024 | 606,000.00 |
| Mar 31, 2024 | 599,000.00 |
| Mar 31, 2024 | 599,000.00 |
| Dec 31, 2023 | 628,000.00 |
| Dec 31, 2023 | 628,000.00 |